You are here

Article Text

Article menu
Download PDFPDF
New targets III
Toll-like receptor 2 signalling and inflammation
  1. F Y Liew,
  2. M Patel,
  3. D Xu
  1. Division of Immunology, Infection and Inflammation, University of Glasgow, Glasgow, UK
  1. Correspondence to:
    F Y Liew
    Division of Immunology, Infection and Inflammation, University of Glasgow, Glasgow G11 6NT, UK; f.y.liewclinmed.gla.ac.uk

https://doi.org/10.1136/ard.2005.042515

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Toll-like receptors (TLRs) are a family of proteins that are involved in the initial phase of host defence against invading pathogens. TLRs act as primary sensors of microbial products and activate signalling pathways that lead to the induction of immune and inflammatory genes.1 TLRs belong to a broader family of proteins, which include receptors for the proinflammatory cytokines interleukin (IL)-1 and IL-18. All members of this superfamily signal inflammation in a similar manner. This is due to the presence of a conserved protein sequence in the cytosolic domain called the Toll–IL-1 receptor (TIR) domain, which activates common signalling pathways, most notably those leading to the activation of the transcription factor NF-κB (nuclear factor κB) and stress-activated protein kinases.2 Most investigations on TLRs have focused on cells of the innate system. Furthermore, most research on the biological implications of TLRs has centred on infections. This is because the patterns recognised by TLRs are principally from pathogens. We have investigated the potential role of TLRs in an inflammatory disease, asthma.

    Asthma is a chronic inflammatory condition of the airways characterised by airway hyperresponsiveness, inflammatory infiltrates in the bronchial wall containing eosinophils, and elevated serum IgE levels. T helper (Th) 2 lymphocytes are thought to play a key role in the initiation and perpetuation of this airway inflammation.3–5 The prevalence of asthma and allergies has increased dramatically over the past 20 years in developed countries, which cannot be explained by changes in genetic predisposition. Environmental factors, especially in industrialised countries, are now thought to be responsible for this rapid increase in asthma.6,7

    We summarise here our recent data showing that a TLR2 agonist, BLP (bacterial lipoprotein, Pam3CSK4) is highly effective in treating an established murine model of OVA specific asthma.

    BLP REVERSES ESTABLISHED OVA INDUCED AIRWAYS INFLAMMATION

    To investigate the therapeutic potential of BLP in …

    View Full Text